Checkpoint Therapeutics Inc CKPT.OQ CKPT.O is expected to show a fall in quarterly revenue when it reports results on March 20 (estimated) for the period ending December 31 2024
LSEG's mean analyst estimate for Checkpoint Therapeutics Inc is for a loss of 19 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Checkpoint Therapeutics Inc is $4.80, above its last closing price of $3.99.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.15 | -0.15 | -0.23 | Missed | -56.8 |
Jun. 30 2024 | -0.30 | -0.30 | -0.18 | Beat | 41 |
Mar. 31 2024 | -0.29 | -0.27 | -0.33 | Missed | -20.7 |
Dec. 31 2023 | -0.54 | -1.10 | Missed | -102.5 | |
Sep. 30 2023 | -0.75 | -0.76 | -0.29 | Beat | 61.8 |
Jun. 30 2023 | -0.77 | -0.78 | -1.05 | Missed | -34.6 |
Mar. 31 2023 | -1.09 | -1.07 | -0.89 | Beat | 16.6 |
Dec. 31 2022 | -1.30 | -1.31 | -2.29 | Missed | -75.3 |
This summary was machine generated March 18 at 12:39 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。